Hangzhou Tigermed Consulting Co., Ltd. (3347) disclosed that all conditions precedent under the Share Transfer Agreement have been met, and the disposal was completed on March 3, 2026. Upon completion, the target company and its subsidiaries remain subsidiaries of Hangzhou Tigermed Consulting Co., Ltd. (3347), and their financial results will continue to be consolidated into the Frontage Group.
Because this transaction is conducted within the group, there is no material impact on the consolidated statement of financial position of Hangzhou Tigermed Consulting Co., Ltd. (3347).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments